NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 27 2025
0mins
Source: PRnewswire
Merger Announcement: NLS Pharmaceutics and Kadimastem have signed a Memorandum of Understanding to collaborate under the new company, NewCelX, following their anticipated merger.
Focus on Advanced Therapies: The partnership aims to enhance the development of innovative therapies for severe diseases, leveraging Kadimastem's cell therapy solutions and TargetGene's precision gene-editing technologies.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
